BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yan Y, Mahotka C, Heikaus S, Shibata T, Wethkamp N, Liebmann J, Suschek CV, Guo Y, Gabbert HE, Gerharz CD. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer. 2004;91:1349-1357. [PMID: 15328523 DOI: 10.1038/sj.bjc.6602127] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Paskeh MDA, Mirzaei S, Orouei S, Zabolian A, Saleki H, Azami N, Hushmandi K, Baradaran B, Hashmi M, Aref AR, Ertas YN, Zarrabi A, Ashrafizadeh M, Samarghandian S. Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. Int J Biol Macromol 2021;191:727-37. [PMID: 34562537 DOI: 10.1016/j.ijbiomac.2021.09.089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ahmad I, Irfan S, Ali Beg MM, Kamli H, Ali SP, Begum N, Alshahrani MY, Rajagopalan P. The SMAC mimetic AT-101 exhibits anti-tumor and anti-metastasis activity in lung adenocarcinoma cells by the IAPs/ caspase-dependent apoptosis and p65-NFƙB cross-talk. Iran J Basic Med Sci 2021;24:969-77. [PMID: 34712428 DOI: 10.22038/ijbms.2021.56400.12586] [Reference Citation Analysis]
3 Li F, Aljahdali IAM, Zhang R, Nastiuk KL, Krolewski JJ, Ling X. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J Exp Clin Cancer Res 2021;40:254. [PMID: 34384473 DOI: 10.1186/s13046-021-02026-1] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
4 Millet-Boureima C, He S, Le TBU, Gamberi C. Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease. Int J Mol Sci 2021;22:3918. [PMID: 33920158 DOI: 10.3390/ijms22083918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu TS, Chen C, Zhou B, Xia BW, Chen ZP, Yan Y. Isobaric tags for relative and absolute quantitation-based quantitative proteomic analysis of X-linked inhibitor of apoptosis and H2AX in etoposide-induced renal cell carcinoma apoptosis. Chin Med J (Engl) 2019;132:2941-9. [PMID: 31855962 DOI: 10.1097/CM9.0000000000000553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Sallas ML, Zapparoli D, Dos Santos MP, Pereira JN, Orcini WA, Peruquetti RL, Chen ES, de Arruda Cardoso Smith M, Payão SLM, Rasmussen LT. Dysregulated Expression of Apoptosis-Associated Genes and MicroRNAs and Their Involvement in Gastric Carcinogenesis. J Gastrointest Cancer 2021;52:625-33. [PMID: 32583363 DOI: 10.1007/s12029-019-00353-3] [Reference Citation Analysis]
7 Zhao XY, Wang XY, Wei QY, Xu YM, Lau ATY. Potency and Selectivity of SMAC/DIABLO Mimetics in Solid Tumor Therapy. Cells 2020;9:E1012. [PMID: 32325691 DOI: 10.3390/cells9041012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
8 Nawasreh MM, Alzyoud EI, Al-Mazaydeh ZA, Rammaha MS, Yasin SR, Tahtamouni LH. Biological activity and apoptotic signaling pathway of C11-functionalized cephalostatin 1 analogues. Steroids 2020;158:108602. [PMID: 32092307 DOI: 10.1016/j.steroids.2020.108602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Li G, Wang X, Li C, Hu S, Niu Z, Sun Q, Sun M. Piwi-Interacting RNA1037 Enhances Chemoresistance and Motility in Human Oral Squamous Cell Carcinoma Cells. Onco Targets Ther 2019;12:10615-27. [PMID: 31824169 DOI: 10.2147/OTT.S233322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Ma HL, Yu SJ, Chen J, Ding XF, Chen G, Liang Y, Pan JL. CA8 promotes RCC proliferation and migration though its expression level is lower in tumor compared to adjacent normal tissue. Biomed Pharmacother 2020;121:109578. [PMID: 31715371 DOI: 10.1016/j.biopha.2019.109578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chen C, Liu TS, Zhao SC, Yang WZ, Chen ZP, Yan Y. XIAP impairs mitochondrial function during apoptosis by regulating the Bcl-2 family in renal cell carcinoma. Exp Ther Med 2018;15:4587-93. [PMID: 29731840 DOI: 10.3892/etm.2018.5974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
12 Pérez-Valencia JA, Prosdocimi F, Cesari IM, da Costa IR, Furtado C, Agostini M, Rumjanek FD. Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer. Sci Rep 2018;8:2007. [PMID: 29386520 DOI: 10.1038/s41598-017-19010-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Martin-Sanchez D, Fontecha-Barriuso M, Sanchez-Niño MD, Ramos AM, Cabello R, Gonzalez-Enguita C, Linkermann A, Sanz AB, Ortiz A. Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. Cell Death Dis 2018;9:118. [PMID: 29371637 DOI: 10.1038/s41419-017-0043-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tahtamouni LH, Nawasreh MM, Al-mazaydeh ZA, Al-khateeb RA, Abdellatif RN, Bawadi RM, Bamburg JR, Yasin SR. Cephalostatin 1 analogues activate apoptosis via the endoplasmic reticulum stress signaling pathway. European Journal of Pharmacology 2018;818:400-9. [DOI: 10.1016/j.ejphar.2017.11.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
15 Wang X, Wang X, Gu J, Zhou M, He Z, Wang X, Ferrone S. Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP. Oncotarget 2017;8:113837-46. [PMID: 29371950 DOI: 10.18632/oncotarget.22985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
16 Chen C, Zhao SC, Yang WZ, Chen ZP, Yan Y. Potential biological process of X-linked inhibitor of apoptosis protein in renal cell carcinoma based upon differential protein expression analysis. Oncol Lett 2018;15:821-32. [PMID: 29403558 DOI: 10.3892/ol.2017.7383] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Yang WZ, Zhou H, Yan Y. XIAP underlies apoptosis resistance of renal cell carcinoma cells. Mol Med Rep. 2018;17:125-130. [PMID: 29115633 DOI: 10.3892/mmr.2017.7925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
18 Qin S, Yang C, Zhang B, Li X, Sun X, Li G, Zhang J, Xiao G, Gao X, Huang G, Wang P, Ren H. XIAP inhibits mature Smac-induced apoptosis by degrading it through ubiquitination in NSCLC. Int J Oncol. 2016;49:1289-1296. [PMID: 27498621 DOI: 10.3892/ijo.2016.3634] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
19 Reiter M, Eckhardt I, Haferkamp A, Fulda S. Smac mimetic sensitizes renal cell carcinoma cells to interferon-α-induced apoptosis. Cancer Letters 2016;375:1-8. [DOI: 10.1016/j.canlet.2016.02.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
20 Flanagan L, Kehoe J, Fay J, Bacon O, Lindner AU, Kay EW, Deasy J, McNamara DA, Prehn JH. High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. Radiat Oncol 2015;10:131. [PMID: 26071313 DOI: 10.1186/s13014-015-0437-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
21 Pedersen J, LaCasse EC, Seidelin JB, Coskun M, Nielsen OH. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol Med. 2014;20:652-665. [PMID: 25282548 DOI: 10.1016/j.molmed.2014.09.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 8.6] [Reference Citation Analysis]
22 Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol 2014;4:197. [PMID: 25120954 DOI: 10.3389/fonc.2014.00197] [Cited by in Crossref: 99] [Cited by in F6Publishing: 124] [Article Influence: 12.4] [Reference Citation Analysis]
23 Wang DG, Sun YB, Ye F, Li W, Kharbuja P, Gao L, Zhang DY, Suo J. Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells. Mol Cell Biochem 2014;386:143-52. [PMID: 24136460 DOI: 10.1007/s11010-013-1853-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
24 Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in oncology. Onco Targets Ther 2013;9:1285-304. [PMID: 24092992 DOI: 10.2147/OTT.S33375] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
25 Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol. 2013;36:239-243. [PMID: 22441342 DOI: 10.1097/coc.0b013e3182467a13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
26 Li S, Sun J, Yang J, Zhang L, Wang L, Wang X, Guo Z. XIAP expression is associated with pancreatic carcinoma outcome. Mol Clin Oncol 2013;1:305-8. [PMID: 24649165 DOI: 10.3892/mco.2013.58] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
27 LaCasse EC. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett 2013;332:215-24. [PMID: 22776562 DOI: 10.1016/j.canlet.2012.06.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
28 Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109-124. [PMID: 22293567 DOI: 10.1038/nrd3627] [Cited by in Crossref: 547] [Cited by in F6Publishing: 518] [Article Influence: 54.7] [Reference Citation Analysis]
29 Zhang Y, Zhu J, Tang Y, Li F, Zhou H, Peng B, Zhou C, Fu R. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol 2011;6:49. [PMID: 21645409 DOI: 10.1186/1746-1596-6-49] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
30 Flanagan L, Sebastià J, Tuffy LP, Spring A, Lichawska A, Devocelle M, Prehn JH, Rehm M. XIAP impairs Smac release from the mitochondria during apoptosis. Cell Death Dis. 2010;1:e49. [PMID: 21364655 DOI: 10.1038/cddis.2010.26] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
31 Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, Wolska A, Szmigielska-Kaplon A, Czemerska M, Pluta P, Robak T, Smolewski P, Wierzbowska A. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res 2010;34:1308-13. [PMID: 20061022 DOI: 10.1016/j.leukres.2009.11.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
32 Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer. 2010;46:800-810. [PMID: 20045309 DOI: 10.1016/j.ejca.2009.11.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
33 Kempkensteffen C, Fritzsche FR, Johannsen M, Weikert S, Hinz S, Dietel M, Riener MO, Moch H, Jung K, Krause H, Miller K, Kristiansen G. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer 2009;9:276. [PMID: 19664236 DOI: 10.1186/1471-2407-9-276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
34 Wang X, Gotoh O. Microarray-based cancer prediction using soft computing approach. Cancer Inform 2009;7:123-39. [PMID: 19718448 DOI: 10.4137/cin.s2655] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
35 Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009;9:125. [PMID: 19397802 DOI: 10.1186/1471-2407-9-125] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 8.2] [Reference Citation Analysis]
36 Zamparese R, Pannone G, Santoro A, Lo Muzio L, Corsi F, Pedicillo MC, Scillitani EL, Tortorella S, Staibano S, Piscuoglio S, Lo Russo L, Bufo P. Survivin expression in renal cell carcinoma. Cancer Invest 2008;26:929-35. [PMID: 19034775 DOI: 10.1080/07357900802017553] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
37 LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27:6252-6275. [PMID: 18931692 DOI: 10.1038/onc.2008.302] [Cited by in Crossref: 350] [Cited by in F6Publishing: 320] [Article Influence: 25.0] [Reference Citation Analysis]
38 Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, Melendez-Zajgla J. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 2008;27:48. [PMID: 18822137 DOI: 10.1186/1756-9966-27-48] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
39 Shibata T, Noguchi T, Takeno S, Gabbert HE, Ramp U, Kawahara K. Disturbed XIAP and XAF1 Expression Balance Is an Independent Prognostic Factor in Gastric Adenocarcinomas. Ann Surg Oncol 2008;15:3579-87. [DOI: 10.1245/s10434-008-0062-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
40 O'Connor CL, Anguissola S, Huber HJ, Dussmann H, Prehn JH, Rehm M. Intracellular signaling dynamics during apoptosis execution in the presence or absence of X-linked-inhibitor-of-apoptosis-protein. Biochim Biophys Acta 2008;1783:1903-13. [PMID: 18590777 DOI: 10.1016/j.bbamcr.2008.05.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
41 Park SH, Park JY, Weiss RH. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol 2008;180:352-60. [PMID: 18499163 DOI: 10.1016/j.juro.2008.02.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
42 Hueber PA, Iglesias D, Chu LL, Eccles M, Goodyer P. In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Lett 2008;265:148-55. [PMID: 18439754 DOI: 10.1016/j.canlet.2008.02.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
43 Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, Motoyama T, Tomita Y. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer 2008;98:941-9. [PMID: 18283311 DOI: 10.1038/sj.bjc.6604268] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
44 Kempkensteffen C, Hinz S, Christoph F, Krause H, Magheli A, Schrader M, Schostak M, Miller K, Weikert S. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2008;134:543-550. [PMID: 17922292 DOI: 10.1007/s00432-007-0317-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
45 Shibata T, Mahotka C, Wethkamp N, Heikaus S, Gabbert HE, Ramp U. Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn Mol Pathol. 2007;16:1-8. [PMID: 17471152 DOI: 10.1097/01.pdm.0000213471.92925.51] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
46 Drosopoulos K, Pintzas A. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects. Expert Opin Ther Targets 2007;11:641-59. [PMID: 17465723 DOI: 10.1517/14728222.11.5.641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
47 Kempkensteffen C, Hinz S, Schrader M, Christoph F, Magheli A, Krause H, Schostak M, Miller K, Weikert S. Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: correlations with pathology and outcome. Cancer Lett. 2007;254:227-235. [PMID: 17449173 DOI: 10.1016/j.canlet.2007.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
48 Kempkensteffen C, Hinz S, Christoph F, Köllermann J, Krause H, Schrader M, Schostak M, Miller K, Weikert S. Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance. Int J Cancer. 2007;120:1081-1086. [PMID: 17154176 DOI: 10.1002/ijc.22416] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
49 Kempkensteffen C, Jäger T, Bub J, Weikert S, Hinz S, Christoph F, Krause H, Schostak M, Miller K, Schrader M. The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours. Int J Androl. 2007;30:476-483. [PMID: 17298543 DOI: 10.1111/j.1365-2605.2006.00742.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
50 Martinez-Velazquez M, Melendez-Zajgla J, Maldonado V. Apoptosis induced by cAMP requires Smac/DIABLO transcriptional upregulation. Cell Signal 2007;19:1212-20. [PMID: 17320350 DOI: 10.1016/j.cellsig.2007.01.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
51 Khasawneh MK, Bukowski RM. Pathways of Dysregulation in Renal Cell Carcinoma: Rational Approaches to Development of Novel Treatment. Clinical Genitourinary Cancer 2006;5:S7-S18. [DOI: 10.3816/cgc.2006.s.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
52 Shaheen PE, Bukowski RM. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm. Cancer Invest 2006;24:640-56. [PMID: 16982470 DOI: 10.1080/07357900600896315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
53 Hervouet E, Godinot C. Mitochondrial disorders in renal tumors. Mitochondrion 2006;6:105-17. [DOI: 10.1016/j.mito.2006.03.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
54 Hueber P, Waters P, Clarke P, Eccles M, Goodyer P. PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney International 2006;69:1139-45. [DOI: 10.1038/sj.ki.5000136] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
55 Müerköster SS, Lust J, Arlt A, Häsler R, Witt M, Sebens T, Schreiber S, Fölsch UR, Schäfer H. Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 2006;25:3973-81. [PMID: 16474845 DOI: 10.1038/sj.onc.1209423] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
56 Vogler M, Giagkousiklidis S, Genze F, Gschwend JE, Debatin KM, Fulda S. Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene 2005;24:7190-202. [PMID: 16091752 DOI: 10.1038/sj.onc.1208876] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
57 Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2005;92:532-8. [PMID: 15685240 DOI: 10.1038/sj.bjc.6602363] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
58 Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Oncogenes as Novel Targets for Cancer Therapy (Part IV): Regulators of the Cell Cycle and Apoptosis. American Journal of PharmacoGenomics 2005;5:397-407. [DOI: 10.2165/00129785-200505060-00006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]